Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) GlobeNewswire - Tue Nov 4, 7:00AM CST

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04,...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 6:59AM CST

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Oct 30, 6:00AM CDT

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease GlobeNewswire - Sat Oct 25, 8:59AM CDT

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting GlobeNewswire - Thu Oct 23, 7:00AM CDT

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 GlobeNewswire - Mon Oct 20, 7:00AM CDT

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...

PHAT : 14.55 (+2.39%)
Cantor Fitzgerald Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT) Tipranks - Thu Oct 16, 8:50AM CDT

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Phathom Pharmaceuticals today and set a price target of $29.00. The company’s shares opened today at $12.62.Elevate Your Investing...

PHAT : 14.55 (+2.39%)
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT) Tipranks - Tue Oct 14, 8:18AM CDT

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals. The company’s shares closed last Friday at $11.82.Elevate Your Investing Strategy:...

PHAT : 14.55 (+2.39%)
Cantor Fitzgerald Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT) Tipranks - Fri Oct 10, 7:12AM CDT

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Phathom Pharmaceuticals yesterday and set a price target of $29.00. The company’s shares closed yesterday at $11.05.Elevate Your Investing...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals Appoints New Chief Financial Officer Tipranks - Tue Oct 7, 7:44AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Phathom Pharmaceuticals...

PHAT : 14.55 (+2.39%)

Barchart Exclusives

Jamie Dimon Has Long Been Sounding the Economic Alarm. After the Fed’s Latest Rate Cut, Can You Still Bank on JPMorgan Stock? Barchart - Wed Dec 10, 8:10PM CST
A nearly 5% plunge in JPM shares on Tuesday is reason for caution with the leader of U.S. bank stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot